Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Nashville, Tennessee 37232


Acute kidney injury is a major complication of cardiac surgery requiring cardiopulmonary bypass (CPB). Hemolysis and rhabdomyolysis frequently occur during CPB. Hemolysis leads to an increase in free hemoglobin, whereas rhabdomyolysis leads to an increase in myoglobin. Free plasma hemoglobin and myoglobin have been shown to be independent predictors of the acute kidney injury that results from CPB. When these hemeproteins are released into the plasma, they undergo redox cycling, generating radical species that initiate lipid peroxidation and a cascade of oxidative damage to cellular membranes, notably in the kidney. F2-isoprostanes and isofurans are sensitive and specific markers of oxidative stress in vivo, and are increased after CPB, particularly in those patients with acute kidney injury. Acetaminophen inhibits the lipid peroxidation catalyzed by myoglobin and hemoglobin. Moreover, in an animal model of rhabdomyolysis-induced kidney injury, acetaminophen significantly attenuated the decrease in creatinine clearance compared to control. The current proposal tests the central hypothesis that acetaminophen will attenuate the lipid peroxidation associated with the hemolysis and rhabdomyolysis that occur in patients undergoing CPB. Demonstration that acetaminophen inhibits the lipid peroxidation resulting from CPB would provide a rationale for a prospective randomized trial to test the hypothesis that acetaminophen will reduce the acute kidney injury that results from CPB.


Inclusion Criteria: 1. Subjects, 18 to 80 years of age, scheduled for elective cardiac surgery requiring CPB 2. For female subjects, the following conditions must be met: postmenopausal for at least 1 year, or status-post surgical sterilization, or if of childbearing potential, utilizing adequate birth control and a negative urine beta-hcg prior to drug treatment Exclusion Criteria: 1. Allergic reaction to ApAP (acetaminophen) 2. Evidence of severe hepatic impairment (history of liver cirrhosis or total bilirubin >2.0mg/dl) 3. Impaired renal function (serum creatinine >2.0 mg/dl) 4. Emergency surgery 5. Pregnancy 6. Breast-feeding 7. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult 8. History of alcohol or drug abuse 9. Treatment with any investigational drug in the 1 month preceding the study 10. Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study 11. Inability to comply with the protocol, e.g. uncooperative attitude and unlikelihood of completing the study 12. History or evidence of active asthma



Primary Contact:

Principal Investigator
Mias Pretorius, MBChB, MSCI
Vanderbilt University

Backup Contact:


Location Contact:

Nashville, Tennessee 37232
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.